Aurinia Pharmaceuticals Inc (AUPH)
5.16
-0.08
(-1.53%)
USD |
NASDAQ |
May 24, 10:07
Aurinia Pharmaceuticals Research and Development Expense (TTM): 49.64M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 49.64M |
| September 30, 2023 | 49.28M |
| June 30, 2023 | 46.65M |
| March 31, 2023 | 45.53M |
| December 31, 2022 | 44.99M |
| September 30, 2022 | 46.27M |
| June 30, 2022 | 55.36M |
| March 31, 2022 | 53.93M |
| December 31, 2021 | 51.14M |
| September 30, 2021 | 53.16M |
| June 30, 2021 | 45.34M |
| March 31, 2021 | 46.32M |
| December 31, 2020 | 50.33M |
| September 30, 2020 | 50.45M |
| June 30, 2020 | 55.99M |
| March 31, 2020 | 56.07M |
| December 31, 2019 | 52.87M |
| September 30, 2019 | 50.41M |
| June 30, 2019 | 43.77M |
| March 31, 2019 | 43.13M |
| December 31, 2018 | 41.38M |
| September 30, 2018 | 39.23M |
| June 30, 2018 | 38.89M |
| March 31, 2018 | 35.49M |
| December 31, 2017 | 33.93M |
| Date | Value |
|---|---|
| September 30, 2017 | 30.70M |
| June 30, 2017 | 23.24M |
| March 31, 2017 | 18.54M |
| December 31, 2016 | 14.53M |
| September 30, 2016 | 12.72M |
| June 30, 2016 | 14.05M |
| March 31, 2016 | 15.98M |
| December 31, 2015 | 15.98M |
| September 30, 2015 | 15.42M |
| June 30, 2015 | 13.18M |
| March 31, 2015 | 11.40M |
| December 31, 2014 | 9.112M |
| September 30, 2014 | 6.711M |
| June 30, 2014 | 4.802M |
| March 31, 2014 | 2.697M |
| December 31, 2013 | 1.992M |
| September 30, 2013 | 4.603M |
| June 30, 2013 | 4.642M |
| March 31, 2013 | 5.003M |
| December 31, 2012 | 5.472M |
| September 30, 2012 | 3.110M |
| June 30, 2012 | 3.290M |
| March 31, 2012 | 3.602M |
| December 31, 2011 | 3.601M |
| September 30, 2011 | 3.644M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
43.77M
Minimum
Jun 2019
56.07M
Maximum
Mar 2020
49.87M
Average
50.33M
Median
Dec 2020
Research and Development Expense (TTM) Benchmarks
| Acasti Pharma Inc | 4.638M |
| Edesa Biotech Inc | 3.860M |
| Lexaria Bioscience Corp | 2.961M |
| Xenon Pharmaceuticals Inc | 172.25M |
| ESSA Pharma Inc | 23.05M |